KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Return on Capital Employed: 2012-2025

Historic Return on Capital Employed for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Sep 2025 value amounting to -0.03%.

  • Supernus Pharmaceuticals' Return on Capital Employed fell 9.00% to -0.03% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.03%, marking a year-over-year decrease of 9.00%. This contributed to the annual value of 0.08% for FY2024, which is 8.00% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Return on Capital Employed stood at -0.03% for Q3 2025, which was down 158.03% from 0.06% recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Return on Capital Employed high stood at 0.12% for Q1 2021, and its period low was -0.03% during Q3 2025.
  • In the last 3 years, Supernus Pharmaceuticals' Return on Capital Employed had a median value of 0.03% in 2023 and averaged 0.03%.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Return on Capital Employed increased by 8bps in 2024, and later fell by 9bps in 2025.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Return on Capital Employed stood at 0.07% in 2021, then decreased by 2bps to 0.05% in 2022, then fell by 5bps to -0.01% in 2023, then increased by 8bps to 0.08% in 2024, then decreased by 9bps to -0.03% in 2025.
  • Its Return on Capital Employed stands at -0.03% for Q3 2025, versus 0.06% for Q2 2025 and 0.07% for Q1 2025.